REACTOGENICITY OF HETEROLOGOUS MRNA-BASED COVID-19 VACCINE BOOSTER IN YOUNG ADULTS IN INDONESIA- A SHORT COMMUNICATION.
COVID-19 vaccine booster reactogenicity in young adults
DOI:
https://doi.org/10.21010/Ajid%20v17i2.2Keywords:
COVID-19, vaccination, booster, heterologous, mRNA-based vaccineAbstract
Background: Heterologous priming with the inactivated SARS-CoV-2 vaccine (CoronaVac) and boosting with mRNA-based COVID-19 vaccine (Moderna or Pfizer) is currently recommended in Indonesia. The reactogenicity data of these heterologous vaccine regimens are not entirely available, particularly in young adults.The present study, therefore, aimed to evaluate the solicited local and systemic reactions in the first seven days post-vaccination either with Moderna or Pfizer vaccine among previous recipients of two doses of CoronaVac.
Materials and Methods: An electronic-based cross-sectional study was conducted among medical students at the Pelita Harapan University, Banten, Indonesia, who received mRNA-based COVID-19 vaccine following two doses of CoronaVac. Samples were collected using a cluster sampling technique. Comparison between groups was performed by Fisher’s exact test.
Results: A total of 72 participants, with 23 (32%) of which received the Moderna vaccine and 49 (68%) received the Pfizer vaccine, were included in this study. The median age of participants was 21 (IQR 19-22) years old. The most common local and systemic events for mRNA-based COVID-19 vaccines were injection site pain, fever, headache, fatigue, myalgia, and arthralgia. Solicited local and systemic reactions were reported more frequently in Moderna recipients than Pfizer recipients. Most local and systemic reactions were graded as mild to moderate and did not lead to hospitalization.
Conclusions: The reactogenicity of the heterologous prime-boost with CoronaVac and mRNA-based COVID-19 vaccine booster among young adults is reassuring, and no unexpected concerns were identified.
References
References
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemer D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilber P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. (2021). "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine." New England Journal of Medicine 384 (5): 403-16. https://doi.org/10.1056/NEJMoa2035389.
Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Ramos GM, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens GMN. (2021). "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination." Nature Medicine 27 (9): 1525-29. https://doi.org/10.1038/s41591-021-01449-9.
Chapin-Bardales J, Gee J. and Myers T. (2021). "Reactogenicity following receipt of mRNA-based COVID-19 vaccines." Journal of American Medical Association, 325 (21): 2201-2. https://doi.org/10.1001/jama.2021.5374.
Costa Clemens SA, Weckx L, Clemens R, Mendes AVA, Souza AR, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, Salvador N, Franco MM, de Avila
Mendonça RN, Queiroz Oliveira IS, de Freitas Souza BS, Fraga M, Aley P, Bibi S, Cantrell L, Dejnirattisai W, Liu X, Mongkolsapaya J, Supasa P, Screaton GR, Lambe T, Voysey M, Pollard AJ, RHH-001 study team. (2022). "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study." Lancet 399 (10324): 521-9. https://doi.org/10.1016/S0140-6736(22)00094-0.
Food and Drug Administration (2007) Toxicity grading scale for healthy adults and adolescent volunteers enrolled in preventive vaccine clinical trials. Available: https://www.fda.gov/media/73679/download. Accessed 02 February 2022.
Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, Paitoonpong L, Suwanpimolkul G, Torvorapanit P, Pradit R, Sophonphan J, Pucharoen O. (2022). "Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers." Asian Pacific Journal of Allergy and Immunology 40 (3): 269-77. https://doi.org/10.12932/AP-250721-1197.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Fraust SN, COV-BOOST study group. (2021). "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the uk (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial." Lancet 398 (10318): 2258-76. https://doi.org/10.1016/S0140-6736 (21)02717-3.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Valina WV, Cooper D, Frenck Jr RW, Hammitt LL, Türeci Özlem, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. (2020). "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine." New England Journal of Medicine 383 (27): 2603-15. https://doi.org/10.1056/NEJMoa2034577.
Shaw RH, Stuart A, Greenland M, Van-Tam JSN, Snape MD, Com-COV Study Group. (2021). "Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data." Lancet 97 (10289): 2043-6. https://doi.org/10.1016/S0140-6736(21)01115-6.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. (2021). “Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.” Lancet Infectious Diseases 21 (2): 181-92. https://doi.org/S1473-3099 (20)30843-4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 African Journal of Infectious Diseases (AJID)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright: Creative Commons Attribution CC BY This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.
